Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 449, 393 (27 September 2007) | doi:10.1038/449393a; Published online 26 September 2007
Open Innovation Challenges
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
- More Challenges
- Powered by:
nature jobs
Scientist, Plant Biochemist
- Philip Morris International (PMI)
- Neuchatel, Switzerland
Canada Excellence Research Chair in Biofuels and Biorefining Innovation
- University of British Columbia
- Vancouver, British Columbia Canada
Copycat consolidation
Meredith Wadman
Abstract
As more blockbuster drugs come off patent, generic drugmakers face a changing landscape. Meredith Wadman looks at their strategies for survival.
One year ago, Mylan Laboratories was the world's ninth-largest generic drugmaker, a thoroughly American company with American clientele and American operations.Today, on the heels of two major acquisitions, the Pennsylvania-based company has vaulted into the ranks of the top three global generics players.
To read this story in full you will need to login or make a payment (see right).
